Yes, Graves’ disease is an autoimmune condition. It is the most common cause of hyperthyroidism, and it occurs when the immune system produces antibodies that directly stimulate the thyroid gland to overproduce hormones. It affects roughly 3% of women and 0.5% of men worldwide.
How the Immune System Causes Graves’ Disease
In a healthy body, thyroid hormone production is controlled by a signaling molecule from the pituitary gland called TSH. TSH binds to receptors on the thyroid and tells it how much hormone to make. In Graves’ disease, the immune system creates antibodies that mimic TSH and bind to those same receptors. These antibodies, called thyroid-stimulating immunoglobulins (TSI), lock onto the thyroid and tell it to keep producing hormones, regardless of what the body actually needs.
There are different types of these receptor antibodies. Some stimulate hormone production directly, while others promote thyroid cell growth, causing the gland to enlarge (a condition called goiter). Because these antibodies circulate constantly in the bloodstream, the thyroid receives a nonstop “go” signal that the body’s normal feedback system can’t override. The result is an excess of thyroid hormones flooding the body, speeding up metabolism and affecting nearly every organ system.
Who Gets It and Why
Graves’ disease is six times more common in women than men. Genetics play a significant role, and the condition runs in families, often alongside other autoimmune diseases like type 1 diabetes or rheumatoid arthritis.
Smoking is one of the strongest environmental risk factors, at least for women. A study of sex-specific risks found that women who had ever smoked had 2.5 times the odds of developing Graves’ disease compared to women who never smoked. Given how common smoking was in the study population, researchers estimated that smoking accounted for 45% of Graves’ disease cases in women. Interestingly, the same increased risk was not found in men. Stress, infections, and periods of major hormonal change (such as pregnancy or the postpartum period) are also recognized triggers that can set off the disease in people who are genetically susceptible.
Symptoms Beyond the Thyroid
The excess thyroid hormone affects the whole body. Common symptoms include a rapid or irregular heartbeat, unintentional weight loss, heat intolerance, trembling hands, anxiety, irritability, difficulty sleeping, and frequent bowel movements. Many people also notice muscle weakness, particularly in the upper arms and thighs.
What makes Graves’ disease distinct from other causes of hyperthyroidism is that the same antibodies can attack tissues outside the thyroid, especially the eyes and skin. Almost half of people with Graves’ disease report eye-related symptoms such as dryness, grittiness, swelling, or a feeling of pressure behind the eyes. Even when symptoms are mild, imaging reveals enlarged eye muscles in nearly 70% of patients. About 3 to 5% develop severe eye disease, with intense pain, inflammation, and potential vision loss from corneal damage or pressure on the optic nerve.
A smaller number of patients develop skin changes, most often a thickening and reddening of the skin on the shins. Though a physical exam detects this in only about 13% of those with severe eye involvement, subclinical skin changes are more common than that number suggests. Roughly 20% of people with thyroid-related skin disease also develop clubbing of the fingers and toes.
How Graves’ Disease Is Diagnosed
Diagnosis starts with blood tests measuring thyroid hormone levels. In Graves’ disease, levels of the hormones T3 and T4 are elevated, while TSH is suppressed to near zero because the pituitary gland is trying to slow down a thyroid that won’t listen.
The key test that confirms Graves’ disease, rather than another cause of hyperthyroidism, is a blood test for TSH receptor antibodies (TRAb) or thyroid-stimulating immunoglobulins (TSI). These antibodies are highly specific to Graves’ disease. In clinical studies, TSI testing identified Graves’ disease with about 99% sensitivity, meaning it catches nearly every case. TRAb testing is similarly accurate at about 97% sensitivity. When these antibody tests are positive in someone with hyperthyroidism, the diagnosis is essentially confirmed. A thyroid uptake scan can also help, showing diffusely increased activity across the entire gland rather than in a single nodule.
Treatment Options
The goal of treatment is to bring thyroid hormone levels back to normal. There are three main approaches, and the right one depends on the severity of the disease, your age, whether you’re planning pregnancy, and whether you have eye involvement.
Antithyroid medication is the most common first-line treatment worldwide, used as the initial approach in over 90% of uncomplicated cases. These drugs work by blocking the thyroid’s ability to produce hormones. Most people take medication for 12 to 18 months, at which point the drug is tapered to see if the disease has gone into remission. For those at high risk of relapse (younger patients, those with very high antibody levels, or those with large goiters), long-term low-dose medication may be continued.
Radioactive iodine therapy is a second option, often considered when medication doesn’t work, the disease relapses after stopping medication, or someone prefers a one-time treatment. It involves swallowing a capsule containing radioactive iodine, which the thyroid absorbs and which gradually destroys overactive thyroid tissue. The trade-off is that most people eventually become hypothyroid afterward and need lifelong thyroid hormone replacement pills. Radioactive iodine is generally avoided during pregnancy or breastfeeding, and doctors are cautious about using it in people with active, moderate-to-severe eye disease because it can temporarily worsen eye symptoms.
Surgery to remove all or most of the thyroid is the least common initial treatment, chosen in about 1.5% of cases. It tends to be favored when there’s a very large goiter, suspicion of thyroid cancer, or when radioactive iodine isn’t suitable. Like radioactive iodine, surgery results in hypothyroidism requiring daily hormone replacement.
What Remission Looks Like
Graves’ disease can go into remission, particularly after a full course of antithyroid medication, but it also commonly relapses. Persistently high antibody levels after 12 to 18 months of treatment are one of the strongest predictors that the disease will return. When relapse happens, you and your doctor will typically revisit the three treatment options and decide whether to restart medication or pursue a more definitive approach like radioactive iodine or surgery.
Because Graves’ disease is autoimmune, the underlying immune dysfunction doesn’t simply disappear even when thyroid levels normalize. People with Graves’ disease have a somewhat higher likelihood of developing other autoimmune conditions over their lifetime. Regular follow-up with blood tests to monitor thyroid function remains important regardless of which treatment path you take.